版本:
中国

BRIEF-Juno Therapeutics places JCAR015 phase II rocket trial on clinical hold

Nov 23 Juno Therapeutics Inc :

* Juno Therapeutics Inc - clinical hold was initiated after two patients suffered cerebral edema earlier this week

* Juno - one patient died and as of tuesday night other is not expected to recover.

* Juno says company is assessing data from cases and trial and is evaluating its options regarding jcar015 program

* Juno notified FDA of voluntary hold and is working with agency and data and safety monitoring board to determine next steps

* Juno says co's trials and plans for its other CD19-directed car T cell product candidates, including JCAR017, are not affected

* Juno places JCAR015 phase II rocket trial on clinical hold Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐